Kriya Therapeutics Inc. has announced its gene therapy program for thyroid eye disease (TED), KRIYA-586. It is designed to be a one-time, adeno-associated virus (AAV) gene therapy that drives durable expression of a monoclonal antibody blocking the insulin-like growth factor 1 receptor (IGF-1R).
Diabetic retinopathy is the main diabetes complication affecting the eyes, and it leads to irreversible vision loss; oxidative stress and impairment of the retinal Muller cells are among the pathogenic mechanisms. Chinese researchers presented data on adiporon, an agonist of the adiponectin receptor protein 1 (ADPOR1) and ADIPOR2 that plays a crucial role in the metabolism of lipids and glucose, in preclinical mouse models of diabetes induced by streptozotocin.
Hangzhou Yirui Pharmaceutical Technology Co. Ltd. has described N-tetrazolyl aryl urea derivatives acting as bradykinin B1 receptor antagonists reported to be useful for the treatment of age-related macular degeneration, allergic conjunctivitis, pulmonary edema, neuralgia, infectious pneumonia, diabetic retinopathy, SARS-CoV-2 infection (COVID-19) and uveitis.
A Character Biosciences Inc. patent describes polypeptides acting as low-density lipoprotein receptor (LDLR) ligands and reported to be useful for the treatment of age-related macular degeneration (AMD).
Inmed Pharmaceuticals Inc. has identified a lead cannabinol (CBN) analogue candidate, INM-089, to advance into additional in vivo studies for age-related macular degeneration (AMD).
Yale University has identified compounds reported to be useful for the treatment of dry age-related macular degeneration (AMD), Fuchs endothelial corneal dystrophy, cataract, glaucoma and keratoconus.
Abionyx Pharma SA has released new preclinical efficacy results with CER-001 after a single intraocular administration in a uveitis model with severe inflammation.
Researchers from the University of Lausanne and affiliated organizations recently presented data from a study that aimed to identify novel candidate causative genes of visual impairment.
Inflammasome Therapeutics Inc. has received FDA clearance to begin a phase I/II trial of the company’s inflammasome inhibitor for the treatment of geographic atrophy, the most severe form of dry age-related macular degeneration. This is the first clinical trial of an inflammasome inhibitor to treat geographic atrophy. The company’s sustained-release implant contains the first of a new class of inflammasome inhibitor drugs, Kamuvudines, developed by the company and designed to halt the multiple processes that cause geographic atrophy.
RSS
